MX2015004171A - Conjugados de sacaridos no lineales. - Google Patents
Conjugados de sacaridos no lineales.Info
- Publication number
- MX2015004171A MX2015004171A MX2015004171A MX2015004171A MX2015004171A MX 2015004171 A MX2015004171 A MX 2015004171A MX 2015004171 A MX2015004171 A MX 2015004171A MX 2015004171 A MX2015004171 A MX 2015004171A MX 2015004171 A MX2015004171 A MX 2015004171A
- Authority
- MX
- Mexico
- Prior art keywords
- conjugates
- saccharide
- nonlinear
- methods
- saccharide conjugates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Esta memoria descriptiva se refiere a conjugados de sacáridos no lineales que comprenden polisacáridos que se enlazan a por lo menos dos péptidos que comprenden epítopos de células-T y que no tienen epítopos de células-B conformacionales, en donde uno de los péptidos se enlaza a un sacárido interno, de tal manera que los conjugados tienen una estructura ramificada (es decir, no lineal). La memoria descriptiva también proporciona métodos para la elaboración de estos conjugados, métodos para la formulación de estos conjugados en composiciones para usarse como vacunas, y métodos para usar las composiciones con el fin de inducir una respuesta inmunitaria al sacárido capsular. La memoria descriptiva también proporciona un nuevo péptido portador de poliepítopos que comprende al epítopo PV1 del virus de polio. El nuevo péptido portador de poliepítopos se puede utilizar tanto en los conjugados de sacáridos lineales como en los conjugados de sacáridos no lineales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261709093P | 2012-10-02 | 2012-10-02 | |
PCT/EP2013/070496 WO2014053521A2 (en) | 2012-10-02 | 2013-10-02 | Nonlinear saccharide conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015004171A true MX2015004171A (es) | 2015-10-22 |
Family
ID=49293654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015004171A MX2015004171A (es) | 2012-10-02 | 2013-10-02 | Conjugados de sacaridos no lineales. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20160101187A1 (es) |
EP (1) | EP2903650B1 (es) |
JP (1) | JP2015532276A (es) |
KR (1) | KR20150060986A (es) |
CN (1) | CN105307684A (es) |
AU (1) | AU2013326584B2 (es) |
BR (1) | BR112015007126A2 (es) |
CA (1) | CA2885625A1 (es) |
EA (1) | EA201590427A1 (es) |
ES (1) | ES2672996T3 (es) |
IL (1) | IL237826A0 (es) |
MX (1) | MX2015004171A (es) |
SG (1) | SG11201502197XA (es) |
TR (1) | TR201808684T4 (es) |
WO (1) | WO2014053521A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104072765B (zh) * | 2014-07-09 | 2017-07-28 | 中国科学院长春应用化学研究所 | 改性聚乙烯亚胺及其制备方法、药物‑基因载体系统及其制备方法 |
NZ736238A (en) | 2015-05-04 | 2022-07-01 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
EP4309670A2 (en) | 2016-09-02 | 2024-01-24 | Sanofi Pasteur, Inc. | Neisseria meningitidis vaccine |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
GEP20227408B (en) * | 2017-05-05 | 2022-08-25 | Serum Institute Of India Pvt Ltd | Method for removal of impurities from bacterial capsular polysaccharide based preparations |
WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
WO2020010000A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
BR112020026899A2 (pt) | 2018-07-04 | 2021-03-30 | Vaxcyte, Inc. | Melhorias em conjugados imunogênicos |
JP7257021B2 (ja) * | 2018-09-03 | 2023-04-13 | 公立大学法人大阪 | 免疫賦活性乳化剤 |
CN113812409B (zh) * | 2021-11-24 | 2022-03-01 | 山东科大创业生物有限公司 | 防治植物白粉病组合物及其制备方法、应用 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5204098A (en) | 1988-02-16 | 1993-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-protein conjugates |
NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
AU627226B2 (en) | 1988-08-25 | 1992-08-20 | Liposome Company, Inc., The | Influenza vaccine and novel adjuvants |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
EP0872478B1 (en) | 1991-03-01 | 2002-12-18 | Minnesota Mining And Manufacturing Company | Intermediates for the preparation of 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
ATE188613T1 (de) | 1992-06-25 | 2000-01-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
JP4028593B2 (ja) | 1993-03-23 | 2007-12-26 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | 3−o脱アシル化モノホスホリルリピドa含有ワクチン組成物 |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
EP0907738A1 (en) | 1996-04-02 | 1999-04-14 | Smithkline Beecham Corporation | Novel compounds |
JP2000508178A (ja) | 1996-05-14 | 2000-07-04 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
DE69739981D1 (de) | 1996-10-31 | 2010-10-14 | Human Genome Sciences Inc | Streptococcus pneumoniae-Antigene und Impfstoffe |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
WO1998043677A1 (en) * | 1997-03-27 | 1998-10-08 | Institut Pasteur | Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
BR9907884A (pt) | 1998-02-12 | 2000-10-24 | American Cyanamid Co | Composição de vacina, processos para gerar uma resposta imune em um antìgeno pneumocócico, para aumentar resposta de ifn-gama em uma vacina pneumocócica, e para gerar anticorpos de fixação complementar para uma resposta protetora a um patógeno, composição imunogênica, e, processo para gerar uma resposta imune em um antìgeno meningocócico |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
HUP0101619A3 (en) | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
GB9808932D0 (en) * | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
CN101219217A (zh) | 1998-05-07 | 2008-07-16 | 科里克萨有限公司 | 佐剂组合物及其使用方法 |
DE19821859A1 (de) * | 1998-05-15 | 1999-12-09 | M Alexander Schmidt | Darstellung immunogener (Kapsel-)Polysaccharid-Konjugate durch orientierte Kupplung synthetischer T-Zell-Epitope zur Erzeugung von Vakzinen gegen N.meningitidis |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
DE69941574D1 (de) | 1998-08-19 | 2009-12-03 | Baxter Healthcare Sa | Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid |
HU228473B1 (en) | 1998-10-16 | 2013-03-28 | Smithkline Beecham Biolog | Adjuvant systems and vaccines |
US6146902A (en) | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
DE60013773T2 (de) | 1999-02-03 | 2005-11-10 | Biosante Pharmaceuticals, Inc. | Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln |
HUP0202885A3 (en) | 1999-09-24 | 2004-07-28 | Smithkline Beecham Biolog | Vaccines |
TR200200777T2 (tr) | 1999-09-24 | 2002-09-23 | Smithkline Beecham Biologicals S.A. | Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant. |
CN1454091A (zh) | 1999-09-25 | 2003-11-05 | 衣阿华大学研究基金会 | 免疫刺激性核酸 |
US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
AU2001293233A1 (en) | 2000-09-01 | 2002-03-13 | Chiron Corporation | Aza heterocyclic derivatives and their therapeutic use |
BRPI0113757B8 (pt) | 2000-09-11 | 2017-11-07 | Chiron Corp | derivados de quinolinona como inibidores de tirosina quinase |
ES2298269T3 (es) | 2000-09-26 | 2008-05-16 | Idera Pharmaceuticals, Inc. | Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales. |
IL154853A0 (en) | 2000-10-27 | 2003-10-31 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a & b |
AU2002255798A1 (en) | 2001-04-03 | 2002-10-21 | Biosynexus Incorporated | An animal model for enteric pathogens |
ATE447967T1 (de) | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
OA12729A (en) | 2001-11-27 | 2006-06-28 | Anadys Pharmaceuticals Inc | 3-Beta-D ribofuranosylthiazoloÄ4,5-dÜpyridimine nucleosides and uses thereof. |
ATE447404T1 (de) | 2002-03-29 | 2009-11-15 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
CA2493690C (en) | 2002-06-13 | 2011-11-08 | New York University | Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases |
US7250443B2 (en) | 2002-08-23 | 2007-07-31 | Chiron Corporation | Pyrrole based inhibitors of glycogen synthase kinase 3 |
WO2004041157A2 (en) | 2002-09-13 | 2004-05-21 | Chiron Corporation | Group b streptococcus vaccine |
AU2003275954A1 (en) * | 2002-11-08 | 2004-06-07 | Danmarks Fodevareforskning | Preparation of chemically well-defined carbohydrate dendrimer conjugates |
EP1587473A4 (en) | 2002-12-27 | 2008-08-13 | Novartis Vaccines & Diagnostic | THIOSEMICARBAZONES ANTIVIRAL AND IMMUNOSTIMULANTS |
CA2513655C (en) | 2003-01-21 | 2011-11-22 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
EP2258365B1 (en) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
US20100255002A1 (en) | 2003-06-26 | 2010-10-07 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
RU2236257C1 (ru) | 2003-09-15 | 2004-09-20 | Косяков Константин Сергеевич | Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами |
KR20110132416A (ko) | 2004-04-05 | 2011-12-07 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
SI1896065T2 (sl) | 2005-06-27 | 2014-12-31 | Glaxosmithkline Biologicals S.A. | Postopek za pripravo cepiv |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
JP5588874B2 (ja) | 2007-11-26 | 2014-09-10 | ノバルティス アーゲー | アジュバント添加されたグルカン |
ES2812523T3 (es) * | 2009-09-30 | 2021-03-17 | Glaxosmithkline Biologicals Sa | Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8 |
CA2801922A1 (en) * | 2010-06-11 | 2011-12-15 | Sloan-Kettering Institute For Cancer Research | Multivalent glycopeptide constructs and uses thereof |
-
2013
- 2013-10-02 EA EA201590427A patent/EA201590427A1/ru unknown
- 2013-10-02 MX MX2015004171A patent/MX2015004171A/es unknown
- 2013-10-02 US US14/432,848 patent/US20160101187A1/en not_active Abandoned
- 2013-10-02 KR KR1020157011597A patent/KR20150060986A/ko not_active Application Discontinuation
- 2013-10-02 BR BR112015007126A patent/BR112015007126A2/pt active Search and Examination
- 2013-10-02 EP EP13771153.7A patent/EP2903650B1/en active Active
- 2013-10-02 JP JP2015533636A patent/JP2015532276A/ja active Pending
- 2013-10-02 CN CN201380062942.6A patent/CN105307684A/zh active Pending
- 2013-10-02 ES ES13771153.7T patent/ES2672996T3/es active Active
- 2013-10-02 CA CA2885625A patent/CA2885625A1/en not_active Abandoned
- 2013-10-02 AU AU2013326584A patent/AU2013326584B2/en not_active Ceased
- 2013-10-02 TR TR2018/08684T patent/TR201808684T4/tr unknown
- 2013-10-02 SG SG11201502197XA patent/SG11201502197XA/en unknown
- 2013-10-02 WO PCT/EP2013/070496 patent/WO2014053521A2/en active Application Filing
-
2015
- 2015-03-19 IL IL237826A patent/IL237826A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20150060986A (ko) | 2015-06-03 |
US20160101187A1 (en) | 2016-04-14 |
CN105307684A (zh) | 2016-02-03 |
SG11201502197XA (en) | 2015-04-29 |
ES2672996T3 (es) | 2018-06-19 |
BR112015007126A2 (pt) | 2017-08-08 |
CA2885625A1 (en) | 2014-04-10 |
IL237826A0 (en) | 2015-05-31 |
WO2014053521A2 (en) | 2014-04-10 |
EP2903650B1 (en) | 2018-04-04 |
EA201590427A1 (ru) | 2015-09-30 |
AU2013326584B2 (en) | 2016-12-01 |
EP2903650A2 (en) | 2015-08-12 |
AU2013326584A1 (en) | 2015-05-07 |
WO2014053521A3 (en) | 2014-07-17 |
JP2015532276A (ja) | 2015-11-09 |
TR201808684T4 (tr) | 2018-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015004171A (es) | Conjugados de sacaridos no lineales. | |
PH12015501814B1 (en) | Novel insulin analog and use thereof | |
PH12017500727A1 (en) | Modified virus-like particles of cmv | |
MX342716B (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
MX2021006342A (es) | Mutantes de virus de influenza y usos para los mismos. | |
PH12015501519A1 (en) | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant | |
ZA201301013B (en) | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells | |
EA201300915A1 (ru) | Новый европейский штамм prrsv | |
MX2015008847A (es) | Composiciones inmunogenicas de virus de influenza y usos de las mismas. | |
EA201692374A2 (ru) | Наноносители, вызывающие иммунную толерантность, для снижения ответной реакции антител | |
EA201490258A1 (ru) | Составы парентеральной норовирусной вакцины | |
IN2012DN01898A (es) | ||
TR201802380T4 (tr) | Benzonaftiridin içeren aşılar. | |
NZ715459A (en) | A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same | |
EA201391183A1 (ru) | Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин | |
MX2015002482A (es) | Composicion inmunogenica. | |
NZ630831A (en) | Compositions and methods for administration of vaccines against dengue virus | |
WO2012047267A3 (en) | Polyvalent immunogen | |
IN2015DN03026A (es) | ||
EP2521733A4 (en) | HIGHLY CONSERVED HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) AND SMALL-VARIANT SEQUENCES THEREOF AS AIMS FOR VACCINATORY AND DIAGNOSIS USES | |
WO2012103444A3 (en) | Immunogenic compositions and reagents for preparing | |
MX367780B (es) | Complejo inmunogénico para vacunación y método de obtención. | |
WO2012071521A3 (en) | Adjuvant | |
NZ714544A (en) | Methods for preparing inactivated rotavirus | |
EA201391202A1 (ru) | Способ получения множественных антигенных гликопептид-углеводных конъюгатов |